279 related articles for article (PubMed ID: 23365488)
1. An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes.
Puddu A; Mach F; Nencioni A; Viviani GL; Montecucco F
Mediators Inflamm; 2013; 2013():591056. PubMed ID: 23365488
[TBL] [Abstract][Full Text] [Related]
2. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
[TBL] [Abstract][Full Text] [Related]
3. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review.
Baggio LL; Drucker DJ
Treat Endocrinol; 2002; 1(2):117-25. PubMed ID: 15765627
[TBL] [Abstract][Full Text] [Related]
5. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
Lam NT; Kieffer TJ
Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
[TBL] [Abstract][Full Text] [Related]
6. Activation of Transmembrane Bile Acid Receptor TGR5 Modulates Pancreatic Islet α Cells to Promote Glucose Homeostasis.
Kumar DP; Asgharpour A; Mirshahi F; Park SH; Liu S; Imai Y; Nadler JL; Grider JR; Murthy KS; Sanyal AJ
J Biol Chem; 2016 Mar; 291(13):6626-40. PubMed ID: 26757816
[TBL] [Abstract][Full Text] [Related]
7. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control.
Lee YS; Jun HS
Mediators Inflamm; 2016; 2016():3094642. PubMed ID: 27110066
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
10. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
Drucker DJ
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
[TBL] [Abstract][Full Text] [Related]
11. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
Lee YS; Jun HS
Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
[TBL] [Abstract][Full Text] [Related]
12. Biological actions and therapeutic potential of the glucagon-like peptides.
Drucker DJ
Gastroenterology; 2002 Feb; 122(2):531-44. PubMed ID: 11832466
[TBL] [Abstract][Full Text] [Related]
13. The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications.
Madsbad S
Diabetes Obes Metab; 2014 Jan; 16(1):9-21. PubMed ID: 23617798
[TBL] [Abstract][Full Text] [Related]
14. Is glucagon-like peptide 1 an incretin hormone?
Nauck MA
Diabetologia; 1999 Mar; 42(3):373-9. PubMed ID: 10096792
[TBL] [Abstract][Full Text] [Related]
15. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
16. Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists.
Ghosh P; Fontanella RA; Scisciola L; Pesapane A; Taktaz F; Franzese M; Puocci A; Ceriello A; Prattichizzo F; Rizzo MR; Paolisso G; Barbieri M
Theranostics; 2023; 13(14):4872-4884. PubMed ID: 37771773
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.
Sourris KC; Ding Y; Maxwell SS; Al-Sharea A; Kantharidis P; Mohan M; Rosado CJ; Penfold SA; Haase C; Xu Y; Forbes JM; Crawford S; Ramm G; Harcourt BE; Jandeleit-Dahm K; Advani A; Murphy AJ; Timmermann DB; Karihaloo A; Knudsen LB; El-Osta A; Drucker DJ; Cooper ME; Coughlan MT
Kidney Int; 2024 Jan; 105(1):132-149. PubMed ID: 38069998
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 structure, function and potential use for NIDDM.
Gefel D; Barg Y; Zimlichman R
Isr J Med Sci; 1997 Oct; 33(10):690-5. PubMed ID: 9397146
[TBL] [Abstract][Full Text] [Related]
19. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
[TBL] [Abstract][Full Text] [Related]
20. Effect of GLP-1 based therapies on diabetic dyslipidemia.
Patel VJ; Joharapurkar AA; Shah GB; Jain MR
Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]